Overview

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Status:
Completed
Trial end date:
2019-05-30
Target enrollment:
Participant gender:
Summary
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe hidradenitis suppurativa (HS).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Adalimumab